LONDON — Cosopt (dorzolamide HCl, timolol maleate ophthalmic solution, Merck) significantly accelerates retinal circulation compared with timolol alone and lowers intraocular pressure (IOP) more than ...
XALACOM® more effective than Cosopt® for IOP reduction in patients with glaucoma or ocular hypertens
Fort Lauderdale, Florida, USA (May 8, 2002) – XALACOM® (fixed combination latanoprost 0.005% and timolol 0.5%) once-daily is more effective for the reduction of intraocular pressure (IOP) than Cosopt ...
A nationwide shortage of a special kind of eye drop to treat glaucoma has hit close to home for one Franklin teenager. On January 24, the Food and Drug Administration placed Dorzolamide Hydrochloride ...
Please provide your email address to receive an email when new articles are posted on . SYDNEY — Xalcom once daily proved more effective for the reduction of IOP than Cosopt twice daily in patients ...
COSOPT PF (dorzolamide HCl, timolol maleate) 2%, 0.5% ophthalmic solution by Merck Cosopt PF (dorzolamide HCl 2%, timolol maleate 0.5% ophthalmic solution), the preservative-free formulation of Cosopt ...
Lannett announced that it has received approval for Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, the generic version of Oak’s Cosopt. Cosopt ophthalmic solution is indicated for use in ...
ROCKVILLE, Md. The Food and Drug Administration has approved Sandoz generic versions of Merck’s Cosopt eye drops, FDA records show. The drops will be sold as dorzolamide hydrochloride and a ...
The company will pay nearly $53 million in the deal. All three products are eye drop solutions. AzaSite treats bacterial conjunctivitis, a type of infection, while COSOPT and COSOPT PF help lower ...
COSOPT® (dorzolamide hydrochloride - timolol maleate ophthalmic solution), the first eyedrop that combines two leading glaucoma medications to dramatically reduce the fluid pressure within the eye ...
WHITEHOUSE STATION, N.J. A patent dispute between Merck and Apotex over Merck’s ophthalmic drug Cosopt has been dismissed by a federal judge. Apotex had filed for a generic version of the drug in ...
These ophthalmology products generated annual sales of approximately $400 million in the above-mentioned territories. We note that the patent for Cosopt has expired in a number of major European ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results